Acceptance for free, safe COVID-19 vaccine high among Indian women: Survey
The online survey was conduced between late October and mid-November 2020 with almost 18,000 respondents in 16 countries
New Delhi: COVID-19 vaccine acceptance among pregnant women and mothers is the highest in India, the Philippines and some Latin American countries, according to a survey of 16 countries that asked questions premised on a safe and free preventive with 90% efficacy.
The survey to assess the response of pregnant women and mothers of children younger than 18 years and their willingness to vaccinate themselves and their children was conducted by a led by team from the Harvard T.H. Chan School of Public Health.
The online survey was conduced between late October and mid-November 2020. Almost 18,000 women in 16 countries responded to questions about the hypothetical safe and free COVID-19 vaccine with 90 per cent efficacy, the Harvard researchers said.
Vaccines for COVID-19 are being distributed around the world, but researchers have till now had little data about global COVID-19 vaccine acceptance.
The findings, published in the European Journal of Epidemiology, indicate that vaccine acceptance was highest in India, the Philippines, and all sampled countries in Latin America. It was lowest in Russia, the US, and Australia, the researchers found.
“Our study confirmed that COVID-19 vaccine hesitancy is multi-faceted,” said Harvard Chan School’s Julia Wu, the senior author of the paper.
“The perceived threat of COVID-19, level of trust in public health agencies, and existing pre-COVID 19 vaccine attitudes play key roles shaping vaccine acceptance and confidence. Vaccination campaigns should be tailored to alleviate these specific concerns,” Wu said.
On Monday, India expanded its vaccination drive to include people above 60 years of age and those aged between 45 and 59 who have co-morbidities. The two vaccines that have been approved for inoculation in the country are the indigenous Covaxin developed by Hyderabad-based Bharat Biotech, and Covishield, the Oxford-AstraZeneca vaccine being manufactured by the Serum Institute of India in Pune.
While Covishield at two full doses has been shown to have 62% efficacy in Phase-3 clinical trials, Bharat Biotech is yet to publish efficacy data for Covaxin from its phase-3 trials.
Fourteen countries with high cumulative incidences of COVID-19 as of October 28, 2020, were included in the survey — the US, India, Brazil, Russia, Spain, Argentina, Colombia, UK, Mexico, Peru, South Africa, Italy, Chile, and the Philippines. Additionally, Australia and New Zealand were included for the reference given that they had lower incidences of COVID-19.
Predictors examined included COVID-19 vaccine confidence, negative experiences with COVID-19, perception on the risk and seriousness of the disease, public trust, general vaccine attitude, demographics and socioeconomic status.
This survey included women aged 18 years or older, currently pregnant or with at least one child under 18 years of age.
Overall, 52% of pregnant women and 73% of non-pregnant women said they would receive such a vaccine, and 69 per cent of all women surveyed said they would vaccinate their children.
In India, the Philippines, and Latin American countries, the acceptance was above 60% among pregnant women and above 78% among non-pregnant women for themselves.
The survey shows over 75% of mothers indicated they would vaccinate their children.
Vaccine acceptance in the US and Russia was below 45 per cent among pregnant women and less than 56 per cent among non-pregnant women for themselves, and similar to countries with very few COVID-19 cases, such as Australia and New Zealand.